US Food and Drug Administration Shifts to AI-Enhanced Regulatory Review With Elsa 4.0 and HALO

You bought the AI tool. Nobody used it. $200/month gone, and now you're more skeptical than ever. That's not a you problem. That's a deployment problem. Here's what the FDA just quietly proved. The

You bought the AI tool. Nobody used it. $200/month gone, and now you're more skeptical than ever.

That's not a you problem. That's a deployment problem.

Here's what the FDA just quietly proved.

The FDA didn't overhaul everything overnight. They didn't fire their review teams or rebuild from scratch. They layered AI into their existing evidence review process — and the result is faster decisions with the same people, same mission, same standards.

That's the model most AI gurus never teach you. Not replacement. Not revolution. Addition.

The businesses winning with AI right now aren't the ones who went all-in on some $40K platform. They picked one slow, repetitive process — research, summarizing reports, answering customer questions — and tested AI there first. Small scope. Real result. Proof of concept in weeks, not months.

Your action this week: Write down the one task your team does repeatedly that eats 3+ hours. Just that one. That's where your first AI win lives — not in a total transformation.

Small proof beats big promises every time.

What's one tool you bought that your team never actually adopted — and what do you think went wrong?

#AIStrategy #SmallBusiness #BusinessGrowth #AIImplementation

Original Source

Integration with HALO may accelerate evidence synthesis and reduce review timelines, potentially enabling faster patient access to high-impact ...